Adam Boxer, MD, PhD
Associate Professor of Neurology
Dr. Boxer received his MD and PhD degrees as part of the NIH-funded Medical Scientist Training Program at New York University Medical Center. He completed an internship in Internal Medicine at California Pacific Medical Center and a residency in Neurology at Stanford University Medical Center. He completed a fellowship in behavioral neurology at UCSF.
Dr. Boxer is an Associate Professor of Neurology and the Vera and John Graziadio Scholar in Alzheimer’s Disease Research. He directs the Alzheimer’s Disease and Frontotemporal Dementia Clinical Trials Program at the Memory and Aging Center. He participates in the evaluation and management of patients in the Memory and Aging Clinic and attends on the Moffitt Inpatient Neurology Service.
Dr. Boxer’s research uses quantitative eye movement (watch a video on this study) and neuroimaging (MRI and PET) measurements to study the pathophysiology of cognitive and motor impairments in normal aging, mild cognitive impairment, Alzheimer’s disease, frontotemporal lobar degeneration, progressive supranuclear palsy (PSP) and corticobasal degeneration. He is the lead principal investigator of the first US multicenter, randomized, placebo-controlled, clinical trial of a therapeutic agent for frontotemporal dementia (memantine/Namenda®) and an international, phase 2/3, randomized, placebo-controlled trial of the microtubule stabilizing agent, davunetide (NAP, Al-108), for PSP. Dr. Boxer is the recipient of the 2002 Edwin Boldrey Award from the San Francisco Neurological Society, the 2005 John Douglas French Foundation Alzheimer’s Award and a 2009 Hellman Foundation Scientist Award. He also leads the FTD Treatment Study Group (FTSG), a group looking to speed the development of new therapies for FTD.